Tests empagliflozin in children with heart failure
Tests empagliflozin, added to standard care, in children with heart failure.
Plain-language title generated from the registry record
Registry title: the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients
Key facts
- Where
- Cairo, EgyptSee the site
- Phase
- Phase 2
Where in Egypt
- Ain Shams HospitalCairo, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ain Shams University
- Trial code
- NCT07692256
- Record updated
- 9 July 2026
- Original description
the study to investigate the efficacy of empagiflozin in pediatric heart failureRead full original descriptionShow less
the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients
the study to investigate the efficacy of empagiflozin in pediatric heart failure
Inclusion: • Pediatrics (aged 1months-18 years); Confirmed HF diagnosis:; HF will be defined by reduced ventricular systolic function (left ventricular ejection fraction by echocardiography) or impaired ventricular filling (pulmonary capillary wedge pressure > 18 mmHg measured directly and/or the ratio of early diastolic mitral inflow velocity(E) to early diastolic mitral annular velocity (e')( E/e'>14 by echocardiography) with clinical features of congestion and/or low cardiac output; Class III or IV of ROSS classification or BNP level more than 300 pg/mL.
Exclusion: • Pediatric with chronic kidney failure; Avoid initiating empagliflozin in patients with concurrent urinary tract infection (UTI); patients with eGFR <60 mL/minute/1.73 m2 will be excluded; Patients with contraindication to empagliflozin usage which include; eGFR <30 mL/minute/1.73 m2; Hypersensitivity (eg, angioedema) to empagliflozin.